Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.
Findings from epidemiologic studies of oxidative stress biomarkers and breast cancer have been mixed, although no studies have focused on estrogen receptor-negative (ER-) tumors which may be more strongly associated with oxidative stress. We examined prediagnostic plasma fluorescent oxidation products (FlOP), a global biomarker of oxidative stress, and risk of ER- breast cancer in a nested case-control study in the Nurses' Health Study and Nurses' Health Study II. ER- breast cancer cases (n = 355) were matched to 355 controls on age, month/time of day of blood collection, fasting status, menopausal status, and menopausal hormone use. Conditional logistic regression models were used to examine associations of plasma FlOP at three emission wavelengths (FlOP_360, FlOP_320, and FlOP_400) and risk of ER- breast cancer. We did not observe any significant associations between FlOP measures and risk of ER- breast cancer overall; the RRQ4vsQ1 (95 %CI) 0.70 (0.43-1.13), p trend = 0.09 for FlOP_360; 0.91(0.56-1.46), p trend = 0.93 for FlOP_320; and 0.62 (0.37-1.03), p trend = 0.10 for FlOP_400. Results were similar in models additionally adjusted for total carotenoid levels and in models stratified by age and total carotenoids. Although high (vs. low) levels of FIOP_360 and FIOP_400 were associated with lower risk of ER- breast cancer in lean women (body mass index (BMI) < 25 kg/m(2)) but not in overweight/obese women, these differences were not statistically significant (pint = 0.23 for FlOP_360; pint = 0.37 for FlOP_400). Our findings suggest that positive associations of plasma FlOP concentrations and ER- breast cancer risk are unlikely.
Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, 909 Fee Road, East Lansing, MI, 48824, USA. khirko@epi.msu.edu.
Kelly A
http://orcid.org/0000-0002-0050-655X
KA
Hirko
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Renée T
RT
Fortner
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.|Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.|Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, MA, USA.
Susan E
SE
Hankinson
Division of Biostatistics and Epidemiology Department of Environmental Health, University of Cincinnati, Cincinnati, OH, USA.
Tianying
T
Wu
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.|Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
A Heather
AH
Eliassen
D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000453:epidemiology* / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D009726:Nurses; D018384:Oxidative Stress; D011446:Prospective Studies; D062486:Public Health Surveillance; D017382:Reactive Oxygen Species / Q000097:blood*; D011960:Receptors, Estrogen / Q000172:deficiency* / Q000378:metabolism; D012307:Risk Factors
D017382:Reactive Oxygen Species; D011960:Receptors, Estrogen
Breast cancer; Estrogen receptor; Fluorescent oxidation products; Oxidative stress